|
1
|
Asafu-Adjaye EB and Wong SK: Determination
of ginsenosides (ginseng saponins) in dry root powder from Panax
ginseng, Panax quinquefolius, and selected commercial
products by liquid chromatography: interlaboratory study. J AOAC
Int. 86:1112–1123. 2003.PubMed/NCBI
|
|
2
|
Yun TK, Lee YS, Lee YH, Kim SI and Yun HY:
Anticarcinogenic effect of Panax ginseng C.A. Meyer and
identification of active compounds. J Kor Med Sci. 16:S6–S18.
2001.
|
|
3
|
He BC, Gao JL, Luo X, Luo J, Shen J, Wang
L, Zhou Q, Wang YT, Luu HH, Haydon RC, Wang CZ, Du W, Yuan CS, He
TC and Zhang BQ: Ginsenoside Rg3 inhibits colorectal tumor growth
through the down-regulation of Wnt/-catenin signaling. Int J Oncol.
38:437–445. 2011.PubMed/NCBI
|
|
4
|
Kim do Y, Park MW, Yuan HD, Lee HJ, Kim SH
and Chung SH: Compound K induces apoptosis via CAMK-IV/AMPK pathway
in HT-29 colon cancer cells. J Agric Food Chem. 57:10573–10578.
2009.PubMed/NCBI
|
|
5
|
Park HM, Kim SJ, Kim JS and Kang HS:
Reactive oxygen mediated ginsenoside Rg3- and Rh2-induced apoptosis
in hepatoma cells through mitochondrial signaling pathways. Food
Chem Toxicol. 50:2736–2741. 2012. View Article : Google Scholar
|
|
6
|
Mai TT, Moon J, Song Y, Viet PQ, Phuc PV,
Lee JM, Yi TH, Cho M and Cho SK: Ginsenoside F2 induces apoptosis
accompanied by protective autophagy in breast cancer stem cells.
Cancer Lett. 321:144–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shibata S: Chemistry and cancer preventing
activities of ginseng saponins and some related triterpenoid
compounds. J Kor Med. 16:S28–S37. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hwang JW, Oh JH, Yoo HS, Lee YW, Cho CK,
Kwon KR, Yoon JH, Park J, Her S, Lee ZW, Jang IS and Choi JS:
Mountain ginseng extract exhibits anti-lung cancecr activity by
inhibiting the nuclear translocation of NF-κB. Am J Chin Med.
40:187–202. 2012.PubMed/NCBI
|
|
9
|
Lee DG, Jang SI, Hwang JW, Yang KE, Yoon
SJ, Lee ZW, An HJ, Jang IS, Choi JS and Yoo HS: Anti-proliferative
effects of ginsenosides extracted from mountain ginseng on lung
cancer. Chin J Integ Med. (In press).
|
|
10
|
Suh SO, Kroh M, Kim NR, Joh YG and Cho MY:
Effects of red ginseng upon postoperative immunity and survival in
patients with stage III gastric cancer. Am J Chin. 30:483–494.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Crew KD and Neugut AI: Epidemiology of
gastric cancer. World J Gastroenterol. 12:354–362. 2006.
|
|
12
|
Meyer HJ and Wilke H: Treatment strategies
in gastric cancer. Dtsch Arztebl Int. 108:698–706. 2011.
|
|
13
|
Jain VK, Cunningham D and Chau I:
Preoperative and postoperative chemotherapy for gastric cancer.
Surg Oncol Clin N Am. 21:99–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Scartozzi M, Galizia E, Verdecchia L,
Berardi R, Antognoli S, Chiorrini S and Cascinu S: Chemotherapy for
advanced gastric cancer: across the years for a standard of care.
Expert Op Pharmacother. 8:797–908. 2007.PubMed/NCBI
|
|
15
|
Al-Batran SE, Ducreux M and Ohtsu A: mTOR
as a therapeutic target in patients with gastric cancer. Int J
Cancer. 130:491–496. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Attele AS, Wu JA and Yuan CS: Ginseng
pharmacology: multiple consitituents and multiple actions. Biochem
Pharmacol. 58:1685–1693. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Christensen LP: Ginsenosides chemistry,
biosynthesis, analysis, and potential health effects. Adv Food Nutr
Res. 55:1–99. 2009.PubMed/NCBI
|
|
18
|
Kim SM, Lee SY, Cho JS, Son SM, Choi SS,
Yun YP, Yoo HS, Yoon do Y, Oh KW, Han SB and Hong JT: Combination
of ginsenoside Rg3 with docetaxel enhances the susceptibility of
prostate cancer cells via inhibition of NF-kappa B. Eur J
Pharmacol. 631:1–9. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee KY, Park JA, Chung E, Lee YH, Kim SI
and Lee SK: Ginsenoside-Rh2 blocks the cell cycle of SK-HEP-1 cells
at the G1/S boundary by selectively inducing the protein expression
of p27 (kip1). Cancer Lett. 110:193–200. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park JA, Lee KY, Oh YJ, Kim KW and Lee SK:
Activation of caspase-3 protease via a Bcl-2 insensitive pathway
during the process of ginsenoside Rh2-induced apoptosis. Cancer
Lett. 121:73–81. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kang KA, Kim YW, Kim SU, Chae S, Koh YS,
Kim HS, Choo MK, Kim DH and Hyun JW: G1 phase arrest of the cell
cycle by a ginseng metabolite, compound K, in U937 human monocytic
leukemia cells. Arch Pharm Res. 28:685–690. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Slee EA, Adrain C and Martin SJ: Serial
killers: ordering caspase activation events in apoptosis. Cell
Death Differ. 6:1067–1074. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cohen GM: Caspases: the executioners of
apoptosis. Biochem J. 326:1–16. 1997.
|
|
24
|
Mohamad N, Gutiérrez A, Núñez M, Cocca C,
Martín G, Cricco G, Medina V, Rivera E and Bergoc R: Mitochondrial
apoptotic pathways. Biocell. 29:149–161. 2005.
|
|
25
|
Adams JM and Cory S: The Bcl-2 protein
family: arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jourdain A and Martinou JC: Mitochondrial
outer-membrane permeabilization and remodelling in apoptosis. Int J
Biochem Cell Biol. 41:1884–1889. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zinkel S, Gross A and Yang E: BCL2 family
in DNA damage and cell cycle control. Cell Death Differ.
13:1351–1359. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fingar DC and Blenis J: Target of
rapamycin (TOR): an integrator of nutrient and growth factor
signals and coordinator of cell growth and cell progression.
Oncogene. 23:3151–3171. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Graham B and Gibson SB: The two faces of
NFkB in cell survival responses. Cell Cycle. 4:1342–1345. 2005.
View Article : Google Scholar
|
|
31
|
Kaltschmidt B, Kaltschmidt C, Hofmann TG,
Hehner SP, Dröge W and Schmitz ML: The pro- or anti-apoptotic
function of NF-kappaB is determined by the nature of the apoptotic
stimulus. Eur J Biochem. 267:3828–3835. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ghosh S and Baltimore D: Activation in
vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B.
Nature. 344:678–682. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bi WY, Fu BD, Shen HQ, Wei Q, Zhang C,
Song Z, Qin QQ, Li HP, Lv S, Wu SC, Yi PF and Wei XB: Sulfated
derivative of 20(S)-ginsenoside Rh2 inhibits inflammatory cytokines
through MAPKs and NF-kappa B pathways in LPS-induced RAW264.7
macrophages. Inflammation. 35:1659–1668. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim ND, Kim EM, Kang KW, Cho MK, Choi SY
and Kim SG: Ginsenoside Rg3 inhibits phenylephrine-induced vascular
contraction through induction of nitric oxide synthase. Br J
Pharmacol. 40:661–670. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ming Y, Chen Z, Chen L, Lin D, Tong Q,
Zheng Z and Song G: Ginsenoside compound K attenuates metastatic
growth of hepatocellular carcinoma, which is associated with the
translocation of nuclear factor-KB p65 and reduction of matrix
metalloproteinase-2/9. Planta Med. 77:428–433. 2011. View Article : Google Scholar
|
|
36
|
Matsui K, Fine A, Zhu B, Marshak-Rothstein
A and Ju ST: Identification of two NF-kappa B sites in mouse CD95
ligand (Fas ligand) promoter: functional analysis in T cell
hybridoma. J Immunol. 161:3469–3473. 1998.PubMed/NCBI
|
|
37
|
Ravi R, Bedi GC, Engstrom LW, Zeng Q,
Mookerjee B, Gélinas C, Fuchs EJ and Bedi A: Regulation of death
receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB. Nat
Cell Biol. 3:409–416. 2001.
|
|
38
|
Zheng Y, Ouaaz F, Bruzzo P, Singh V,
Gerondakis S and Beg AA: NF-κB RelA (p65) is essential for
TNF-a-induced fas expression but dispensable for both TCR-induced
expression and activation-induced cell death. J Immunol.
166:4949–4957. 2001.
|
